SOUL trial: Oral semaglutide demonstrates a 14% reduction in risk of major adverse CV eventsHeadline results from the SOUL cardiovascular outcomes trial show the trial achieved its primary objective by demonstrating a...
SOUL trial: Oral semaglutide demonstrates a 14% reduction in risk of major adverse CV events1 hour ago